Agenda

Session I Introduction

Seth A. Wander, MD, PhD

‍

Evolving Insights Related to MRD in Early Stage HR+ Breast Cancer

Arielle J. Medford, MD

‍

Optimizing Targeted Therapy for High Risk Early Stage HR+ Breast Cancer

Claudine Isaacs, MD, FRCPC

‍

Leveraging Molecular Tools to Guide Treatment Planning in HR+ Early Breast Cancer

Stephanie L. Graff, MD, FACP, FASCO

‍

Audience Q&A and Panel Discussion

Stephanie L. Graff, MD, FACP, FASCO; Claudine Isaacs, MD, FRCPC; Arielle J. Medford, MD